International archives of allergy and immunology
-
Int. Arch. Allergy Immunol. · Jan 2015
Randomized Controlled Trial Multicenter StudyIcatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3.
In randomized, controlled, double-blind, multicenter phase 3 studies, one icatibant injection was efficacious and generally well tolerated in patients with a single hereditary angioedema (HAE) attack. Here, the efficacy and safety of icatibant for multiple HAE attacks was evaluated across the controlled and open-label extension phases of the For Angioedema Subcutaneous Treatment (FAST)-3 study (NCT00912093). ⋯ Icatibant was efficacious and generally well tolerated across multiple HAE attacks, including laryngeal attacks.